University of Pennsylvania

Sungkyunkwan University

Joo-Sung Yang

David B Weiner

Karuppiah Muthumani

Mathura P Ramanathan

Michele Kutzler

Andrew Y Choo

Jean D Boyer

Jaewhan Song

Wonkyung Oh

Young Hoon Sung

Han-Woong Lee

Suhk Neung Pyo

Eun Hee Yang

Hyeran Cha

Sung Ryul Lee

Sang-Woo Kim

Disclosed is a composition for treating or preventing a viral infection or associated disease comprising a Jab1 protein, a nucleic acid having a nucleotide sequence coding for a Jab1 protein or a recombinant virus expressing a Jab1 protein.

Composition for treating virus infection disease comprising Jab1

Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors are disclosed as well as recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. The immunomodulatory effect following delivery of IL-15 and CD40L, with or without immunogens, is disclosed as are various nucleic acid molecules and compositions thereof used for delivering such proteins and methods of using such compositions.

Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same

The present invention relates to an avian influenza vaccine of plant origin, prepared by transforming a plant with a surface protein of avian influenza virus, hemagglutinin (HA) or neuraminidase (NA), and a method for preparing the same. Further, the present invention relates to an oral vaccine for preventing avian influenza virus, of which mass-production conditions are established, and thus the produced transgenic plant can be more easily, safely, and economically used as a fodder additive. Furthermore, the present invention relates to a reagent for diagnosing avian influenza virus infection, prepared by isolating and purifying a recombinant antigen protein from the transgenic plant.

Plant vector pBSNB-TEV, vectors derived therefrom, and methods of use

Disclosed are primers specific to the genome of HPV genotypes 11, 16, 18 and 31. Also disclosed are a kit for detecting the HPV genome comprising the primers and a method of detecting the HPV genome using the primers.

Primer for detection of human papillomavirus

Substantially pure WIP-1 and its use in assays to identify PAP-1/WIP-1 interaction inhibitors or WIP-I/WNV Cp interaction inhibitors are disclosed. Compositions comprising antisense sequences to prevent expression of WIP-1 and methods of treating cancer using the same are disclosed.

WNV core protein/capsid interacting protein and uses of the same

This invention provides methods of inducing cell death withorcapsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention also provides methods of treating patients suffering from diseases characterized by hyperproliferating cells by administering pharmaceutical compositions comprising WNV or other virus includingorcapsid or other protein or a nucleic acid molecule encoding the same. Methods of identifying compounds which have anti-viral and/or anti-WNV and/or anti-and/or anti-capsid or other protein activity are disclosed. The invention also provides vaccine compositions comprising capsid or other proteins, or fragments thereof, or nucleic acids encoding same, from WNV or other virus includingorand a pharmaceutically acceptable carrier. The invention also provides diagnostic methods and kits for identifying individuals exposed to WNV or other viruses includingor

Method of inducing cell death using West Nile virus capsid protein

The present invention provides methods of producing protein in a recombinant expression system that comprises translation of mRNA transcribed from a heterologous DNA sequence in the expression system, said method comprising the steps of predicting the secondary structure of mRNA transcribed from a native heterologous DNA sequence; modifying the native heterologous DNA sequence to produce a modified heterologous DNA sequence wherein mRNA transcribed from the modified heterologous DNA sequence has a secondary structure having increased free energy compared to that of the secondary structure of the mRNA transcribed from the native heterologous DNA sequence; and using the modified heterologous DNA sequence in the recombinant expression system for protein production. The invention also provides injectable pharmaceutical compositions comprising a nucleic acid molecule that includes a modified coding sequence. The invention also provides recombinant viral vectors comprising a nucleic acid molecule that includes a modified coding sequence.

Growing community of inventors

Seoul, South Korea

Joo-Sung Yang